The locus coeruleus is directly implicated in l-Dopa-Induced dyskinesia in parkinsonian rats: An electrophysiological and behavioural study

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Miguelez, Cristina ^a   Aristieta, Asier ^a   Cenci, Maria Angela ^b   Ugedo, Luisa ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; IBOTENIC ACID; LEVODOPA; AMPHETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DYSKINESIA; ELECTROPHYSIOLOGY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INVOLUNTARY MOVEMENT; LOCUS CERULEUS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSONISM; RAT; ANIMAL; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

PARKINSONIA; RATTUS;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; DYSKINESIAS; ELECTROPHYSIOLOGY; FEMALE; IBOTENIC ACID; LEVODOPA; LOCUS COERULEUS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80052567233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024679     Document Type: Article

References (89)

1. Samii A, Nutt JG, Ransom BR, (2004) Parkinson's disease. Lancet 363: 1783-1793.
2. Kish SJ, Shannak K, Hornykiewicz O, (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
3. Ahlskog JE, Muenter MD, (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
4. Berthet A, Bezard E, (2009) Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord 15 (Suppl 4): S8-12.
5. Cenci MA, Konradi C, (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183: 209-233.
6. Obeso JA, Olanow CW, Nutt JG, (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23: S2-7.
7. Cenci MA, Lindgren HS, (2007) Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 17: 665-671.
8. Mercuri NB, Bernardi G, (2005) The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 26: 341-344.
9. Alachkar A, Brotchie JM, Jones OT, (2010) Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neurosci Res 67: 245-249.
10. Zarow C, Lyness SA, Mortimer JA, Chui HC, (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341.
11. Frisina PG, Haroutunian V, Libow LS, (2009) The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 15: 144-148.
12. Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, et al. (2000) The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 24: 655-668.
13. Hornykiewicz O, (1998) Biochemical aspects of Parkinson's disease. Neurology 51: S2-9.
14. Remy P, Doder M, Lees A, Turjanski N, Brooks D, (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128: 1314-1322.
15. Dekundy A, Lundblad M, Danysz W, Cenci MA, (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179: 76-89.
16. Gomez-Mancilla B, Bedard PJ, (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16: 418-427.
17. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, et al. (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18: 872-883.
18. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM, (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14: 744-753.
19. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, et al. (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16: 642-650.
20. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, et al. (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16: 708-713.
21. Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM, (2009) Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 328: 276-283.
22. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K, (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134.
23. Kaehler ST, Singewald N, Philippu A, (1999) Dependence of serotonin release in the locus coeruleus on dorsal raphe neuronal activity. Naunyn Schmiedebergs Arch Pharmacol 359: 386-393.
24. Kaehler ST, Singewald N, Philippu A, (1999) The release of catecholamines in hypothalamus and locus coeruleus is modulated by peripheral chemoreceptors. Naunyn Schmiedebergs Arch Pharmacol 360: 428-434.
25. Lin Y, Quartermain D, Dunn AJ, Weinshenker D, Stone EA, (2008) Possible dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in behavioral activation. Synapse 62: 516-523.
26. Cedarbaum JM, Aghajanian GK, (1977) Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol 44: 375-385.
27. Elam M, Clark D, Svensson TH, (1986) Electrophysiological effects of the enantiomers of 3-PPP on neurons in the locus coeruleus of the rat. Neuropharmacology 25: 1003-1008.
28. Miguelez C, Grandoso L, Ugedo L, (2010) Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int J Neuropsychopharmacol pp. 1-14.
29. Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A, (2007) Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 14: 2330-2334.
30. Fulceri F, Biagioni F, Ferrucci M, Lazzeri G, Bartalucci A, et al. (2007) Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res 1135: 219-229.
31. Perez V, Sosti V, Rubio A, Barbanoj M, Rodriguez-Alvarez J, et al. (2007) Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur J Pharmacol 576: 83-90.
32. Marin C, Aguilar E, Bonastre M, (2008) Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats. J Neural Transm.
33. Cenci MA, Lee CS, Bjorklund A, (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10: 2694-2706.
34. Szot P, Miguelez C, White SS, Franklin A, Sikkema C, et al. (2010) A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. Neuroscience 166: 279-291.
35. Paxinos G, Watson C, (1997) The Rat Brain in Stereotaxic Coordinates (3rd edn). Orlando Academic Press.
36. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, et al. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96: 1718-1727.
37. Winkler C, Kirik D, Bjorklund A, Cenci MA, (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10: 165-186.
38. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, et al. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15: 120-132.
39. Cenci MA, Lundblad M, (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9: Unit 9 25.
40. Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, et al. (2005) Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain 128: 559-569.
41. Lee CS, Cenci MA, Schulzer M, Bjorklund A, (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (Pt7): 1365-1379.
42. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA, (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112: 1465-1476.
43. Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA, (2007) The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177: 150-159.
44. Miguelez C, Fernandez-Aedo I, Torrecilla M, Grandoso L, Ugedo L, (2009) alpha(2)-Adrenoceptors mediate the acute inhibitory effect of fluoxetine on locus coeruleus noradrenergic neurons. Neuropharmacology 56: 1068-1073.
45. Grace AA, Bunney BS, (1984) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4: 2877-2890.
46. Cedarbaum JM, Aghajanian GK, (1976) Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res 112: 413-419.
47. Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, et al. (2001) Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry 50: 510-520.
48. Bilbao G, Ruiz-Ortega JA, Miguens N, Ulibarri I, Linazasoro G, et al. (2006) Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment. Brain Res 1084: 175-184.
49. Morera-Herreras T, Ruiz-Ortega JA, Gomez-Urquijo S, Ugedo L, (2008) Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons. Neuroscience 151: 817-823.
50. Morera-Herreras T, Ruiz-Ortega JA, Ugedo L, (2010) Two opposite effects of Delta(9)-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmission. Synapse 64: 20-29.
51. Boraud T, Bezard E, Bioulac B, Gross CE, (2001) Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124: 546-557.
52. Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, et al. (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 22: 586-598.
53. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, et al. (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67: 1612-1617.
54. Arai A, Tomiyama M, Kannari K, Kimura T, Suzuki C, et al. (2008) Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 62: 632-635.
55. Alachkar A, Brotchie JM, Jones OT, (2011) Changes in the mRNA Levels of alpha(2A) and alpha (2C) Adrenergic Receptors in Rat Models of Parkinson's Disease and L:-DOPA-Induced Dyskinesia. J Mol Neurosci.
56. Hutchinson WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE, (1997) Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 42: 767-775.
57. Chergui K, Akaoka H, Charlety PJ, Saunier CF, Buda M, et al. (1994) Subthalamic nucleus modulates burst firing of nigral dopamine neurones via NMDA receptors. Neuroreport 5: 1185-1188.
58. Dutton A, Dyball RE, (1979) Phasic firing enhances vasopressin release from the rat neurohypophysis. J Physiol 290: 433-440.
59. Lundberg JM, Rudehill A, Sollevi A, Theodorsson-Norheim E, Hamberger B, (1986) Frequency- and reserpine-dependent chemical coding of sympathetic transmission: differential release of noradrenaline and neuropeptide Y from pig spleen. Neurosci Lett 63: 96-100.
60. Gonon FG, (1988) Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24: 19-28.
61. Henry B, Crossman AR, Brotchie JM, (1998) Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151: 334-342.
62. Buck K, Voehringer P, Ferger B, (2010) The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem 112: 444-452.
63. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ, (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361: 181-186.
64. Pineda J, Ruiz-Ortega JA, Ugedo L, (1997) Receptor reserve and turnover of alpha-2 adrenoceptors that mediate the clonidine-induced inhibition of rat locus coeruleus neurons in vivo. J Pharmacol Exp Ther 281: 690-698.
65. Pineda J, Ruiz-Ortega JA, Ugedo L, Garcia-Sevilla JA, (1995) The stimulatory effect of clonidine on locus coeruleus noradrenergic neurons through imidazoline receptors is modulated by excitatory amino acids. Ann N Y Acad Sci 763: 501-505.
66. Ruiz-Ortega JA, Ugedo L, Pineda J, Garcia-Sevilla JA, (1995) The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin. Naunyn Schmiedebergs Arch Pharmacol 352: 121-126.
67. Holmberg M, Scheinin M, Kurose H, Miettinen R, (1999) Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 93: 1323-1333.
68. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, et al. (1994) Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21: 133-149.
69. Rosin DL, Talley EM, Lee A, Stornetta RL, Gaylinn BD, et al. (1996) Distribution of alpha 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol 372: 135-165.
70. Perez V, Marin C, Rubio A, Aguilar E, Barbanoj M, et al. (2009) Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. J Neural Transm 116: 1257-1266.
71. Srinivasan J, Schmidt WJ, (2003) Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci 17: 2586-2592.
72. Archer T, Fredriksson A, (2006) Influence of noradrenaline denervation on MPTP-induced deficits in mice. J Neural Transm 113: 1119-1129.
73. Wang Y, Zhang QJ, Liu J, Ali U, Gui ZH, et al. (2010) Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res 1310: 189-199.
74. Fritschy JM, Grzanna R, (1989) Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30: 181-197.
75. Ross SB, (1976) Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br J Pharmacol 58: 521-527.
76. Fritschy JM, Grzanna R, (1991) Experimentally-induced neuron loss in the locus coeruleus of adult rats. Exp Neurol 111: 123-127.
77. Abercrombie ED, Zigmond MJ, (1989) Partial injury to central noradrenergic neurons: reduction of tissue norepinephrine content is greater than reduction of extracellular norepinephrine measured by microdialysis. J Neurosci 9: 4062-4067.
78. Wolfman C, Abo V, Calvo D, Medina J, Dajas F, et al. (1994) Recovery of central noradrenergic neurons one year after the administration of the neurotoxin DSP4. Neurochem Int 25: 395-400.
79. Magnuson DS, Staines WA, Marshall KC, (1993) Electrophysiological changes accompanying DSP-4 lesions of rat locus coeruleus neurons. Brain Res 628: 317-320.
80. Olpe HR, Laszlo J, Dooley DJ, Heid J, Steinmann MW, (1983) Decreased activity of locus coeruleus neurons in the rat after DSP-4 treatment. Neurosci Lett 40: 81-84.
81. Gibson CJ, (1988) Increase in mouse brain regional noradrenaline turnover after L-dopa administration. J Pharm Pharmacol 40: 258-261.
82. Cenci M, (2009) Pathophysiology of L-DOPA-Induced Dyskinesia in Parkinson's Disease. In: Dunnett S, Iverson S, Iverson LL, editors. Dopamine Handbook New York, NY Oxford University Press pp. 434-444.
83. Arai R, Horiike K, Hasegawa Y, (1998) Dopamine-degrading activity of monoamine oxidase in locus coeruleus and dorsal raphe nucleus neurons. A histochemical study in the rat. Neurosci Lett 250: 41-44.
84. Hida T, Arai R, (1998) Monoamine oxidase activity in noradrenaline neurons of the locus coeruleus of the rat. A double-labeling histochemical study. Brain Res 814: 209-212.
85. Mela F, Marti M, Dekundy A, Danysz W, Morari M, et al. (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101: 483-497.
86. Alachkar A, Brotchie J, Jones OT, (2006) alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata. Neurosci Lett 395: 138-142.
87. Berretta N, Bernardi G, Mercuri NB, (2000) Alpha(1)-adrenoceptor-mediated excitation of substantia nigra pars reticulata neurons. Neuroscience 98: 599-604.
88. Gehlert DR, Gackenheimer SL, Robertson DW, (1993) Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 157: 203-206.
89. Gehlert DR, Schober DA, Gackenheimer SL, (1995) Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem 64: 2792-2800.